
Bristol-Myers (BMY) Stock Forecast & Price Target
Bristol-Myers (BMY) Analyst Ratings
Bulls say
Bristol-Myers Squibb is experiencing a positive shift in its outlook due to increased probability of success (PoS) for key drug candidates, with milvexian and iber/mezi now projected to contribute a combined risk-adjusted sales of approximately $4.8 billion by 2033. The company's robust guidance surpasses sell-side consensus, alleviating previous market concerns and fostering optimism regarding its pipeline, particularly in the immuno-oncology and cardiovascular sectors. Furthermore, the firm maintains a strong financial position characterized by effective cost management, stable growth from its existing portfolio, and the provision of a sustainable dividend, all contributing to a solid foundation for future growth.
Bears say
Bristol-Myers Squibb's stock faces a negative outlook due to significant delays in the regulatory approval and launch of new products, which could adversely affect revenues and earnings. The company's valuation remains below the average forward EV/EBITDA multiple of its peer group, indicating potential underperformance compared to competitors. Additionally, risks associated with clinical trials, such as regulatory setbacks and evolving market preferences, further exacerbate concerns about the firm's ability to maintain its competitive edge in the pharmaceutical market.
This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.
Bristol-Myers (BMY) Analyst Forecast & Price Prediction
Start investing in Bristol-Myers (BMY)
Order type
Buy in
Order amount
Est. shares
0 shares